1), the corresponding figures were 44% for sensitivity and 55% for specificity, with a positive predictive value of 44% and a negative predictive value of 55%, respectively. Overall, among 36 1-2 Alectinib molecular weight cm indeterminate nodules the modified

algorithm would have diagnosed 7 (44%) of tumors only of the 16 identified by histology, including 15 HCC and 1 intrahepatic cholangiocarcinoma (ICC). At the same time, the diagnosis of HCC would have been significantly delayed in nine (56%) patients compared with none if treated according to AASLD guidelines. The fact that the majority (75%) of delayed diagnoses were in patients with a very early HCC, i.e., the ideal candidates for radical treatment with local ablation,4 attenuates the appeal of the modified algorithm, which in addition would have also led to a misdiagnosis of ICC in one nodule devoid of contrast uptake

during the arterial phase of CT/MRI. Due to the high incidence of HCC in patients with compensated cirrhosis and the low risk of liver biopsy complications, we strongly endorse unmodified AASLD guidelines for the management of patients with cirrhosis with 1-2 cm liver nodules with undefined radiological BIBW2992 concentration diagnosis. Massimo Iavarone M.D.*, Angelo Sangiovanni M.D.*, * A.M. & A. Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Maggiore Hospital, University of Milan, Milan, Italy. “
“Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and leads to cirrhosis and hepatocellular carcinoma in a significant proportion of infected individuals. In developed countries, the use of intravenous illicit drugs is the main mechanism of HCV transmission. Treatment of chronic hepatitis C is currently based on interferon and ribavirin, with sustained virological response rates around 50%. Specific antivirals directed against the HCV protease MCE and polymerase are already in phase II and phase III clinical trials and will increase significantly the chances of viral eradication in treated patients. “
“Spontaneous

bacterial peritonitis (SBP) is a life-threatening infection of ascites in the absence of an intra-abdominal source of infection and with no obvious source of infection. SBP is observed predominantly in patients with advanced cirrhosis. Gram-negative aerobic bacteria are causative in approximately 80% of patients and anaerobic bacteria occur in no more than 5% of patients, but the prevalence of multidrug resistant organisms is increasing. Diagnostic paracentesis with ascitic fluid analysis (polymorphonuclear leukocyte (PMN) count and culture) is the cornerstone of diagnosis. A presumptive diagnosis of SBP is made with 250 PMN/mm3 ascites – the definitive diagnosis is established by a positive culture result. Ascitic fluid should be inoculated into culture bottles at the bedside. Primary and secondary prophylaxis improves survival.